Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$78.91 USD

78.91
481,178

-1.39 (-1.73%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $78.91 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

NextGen (NXGN) Behavioral Health Suite to Address Mental Health

by Zacks Equity Research

NextGen's (NXGN) Behavioral Health Suite is expected to ease state reporting and enable the secure sharing of patient information across providers.

Here's Why You Should Invest in HealthEquity (HQY) Stock Now

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Masimo's (MASI) PVi Favored by Study for GDFT in Elderly Patients

by Zacks Equity Research

Masimo's (MASI) non-invasive, continuous PVi is expected to reduce cardiopulmonary complications and fluid administered in elderly patients during GI surgery.

Premier, Inc. (PINC) Tops Q4 Earnings Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.49% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

THRN vs. HQY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

THRN vs. HQY: Which Stock Is the Better Value Option?

Reasons to Retain West Pharmaceutical (WST) Stock for Now

by Zacks Equity Research

West Pharmaceutical's (WST) strength in its proprietary products segment raises optimism about the stock.

Nevro's (NVRO) New Data Supports SCS Therapy for PDN Treatment

by Zacks Equity Research

Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS implant for durable pain relief and significant improvements in patient condition post-implantation.

McKesson (MCK) & Genpact Extend Tie Up to Improve Workflow

by Zacks Equity Research

McKesson's (MCK) latest partnership extension is likely to transform its finance operations for enhanced service and competitive growth.

Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and InMode (INMD) have performed compared to their sector so far this year.

AngioDynamics' (ANGO) New FDA Recognition to Boost Treatment

by Zacks Equity Research

The FDA's grant of the Breakthrough Device designation for AngioDynamics' (ANGO) AngioVac is likely to remove thrombus and embolic material and minimize blood loss via blood recirculation.

Patterson Companies (PDCO) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) broad product line.

3 Reasons to Retain DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

Biote Corp. (BTMD) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of 340% and 5.33%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Apollo Medical Holdings, Inc. (AMEH) Meets Q2 Earnings Estimates

by Zacks Equity Research

Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of 0% and 2.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

BD (BDX) Receives FDA Nod to Address Critical Infusion Needs

by Zacks Equity Research

The latest regulatory clearance for BD's (BDX) Alaris Infusion System is expected to improve healthcare system efficiency via better care coordination and utilization of actionable information.

Reasons to Add HealthEquity (HQY) Stock to Your Portfolio

by Zacks Equity Research

HealthEquity's (HQY) strength in HSA raises optimism about the stock.

Avantor's (AVTR) New Expansion Plans to Boost Workflow

by Zacks Equity Research

Avantor's (AVTR) latest expansion plans are likely to aid customers in creating customized workflow solutions.

New Strong Buy Stocks for July 20th

by Zacks Equity Research

HQY, SKFRY, AZEK, CIR and ATR have been added to the Zacks Rank #1 (Strong Buy) List on July 20, 2023.

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

by Zacks Equity Research

Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.

Are Medical Stocks Lagging HealthEquity (HQY) This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and McKesson (MCK) have performed compared to their sector so far this year.

Here's Why You Should Add BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Masimo's (MASI) Preliminary Q2 Revenues Dampened by Lower Sales

by Zacks Equity Research

Masimo's (MASI) second-quarter 2023 results are likely to have been dampened by the postponement of orders and increased hospital labor costs, among others.

Inogen (INGN) Inks Buyout Agreement to Expand Product Portfolio

by Zacks Equity Research

Inogen's (INGN) latest acquisition is expected to leverage its commercial infrastructure and capabilities as well as potentially address a large growing bronchiectasis market.

Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.